Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure.
R Katzenschlager, A Schrag, A Evans...
https://pubmed.ncbi.nlm.nih.gov/17679674Actively Recruiting
All Genders
ID07023224
Adaptation of the Parkinson's Disease Dyskinesia Questionnaire into Turkish and Its Validity and Reliability in Parkinson's Patients
Led by Izmir Bakircay University · Updated on 2025-09-19
130
Participants Needed
2
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to validate and test the reliability of the Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) for patients with idiopathic Parkinson's disease. Dyskinesia, which involves involuntary muscle movements, is a common motor complication in Parkinson's disease and can affect daily activities. The study evaluates how well this scale measures dyskinesia impact in Turkish-speaking patients and compares it with other assessments like the Tampa Kinesiophobia Scale, Mini BesTest, Activity Specific Balance Safety Scale, and Parkinson's Disease Questionnaire-39. Participants diagnosed with idiopathic Parkinson's disease who have a dyskinesia score of 1 or higher on the Unified Parkinson's Disease Rating Scale (UPDRS) will be involved. The PDYS-26 scale will be translated into Turkish using a back-translation method and finalized with expert approval. Patients will complete the adapted scale and other related assessments to determine its validity and reliability in the Turkish population. Participants will be assessed at baseline (Day 1) and again seven days later (Day 8) using the PDYS-26. The study includes evaluations through various questionnaires and scales to measure dyskinesia severity, balance, fear of movement, and quality of life. The research team will monitor the participants' responses to ensure the scale's effectiveness and relevance for use in clinical settings with Turkish Parkinson's patients.
CONDITIONS
Brief Title
Reliability and Validity Study of the Turkish Version of the Parkinson's Disease Dyskinesia Scale (PDYS-26)
Who Can Participate
All Genders
Eligibility Criteria
You may qualify if you...
- Diagnosed with idiopathic Parkinson's disease
- Hoehn and Yahr stage between 1 and 3
- Unified Parkinson's Disease Rating Scale (UPDRS) dyskinesia score of 1 or higher
- Agreeing to participate in the study
You will not qualify if you...
- Diagnosis of atypical or secondary parkinsonism
- Severe musculoskeletal, neurological, or cardiopulmonary problems affecting assessment results
- Mini Mental State Examination score below 24
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - 1 week
Participants complete the Turkish version of the Parkinson's Disease Dyskinesia Scale (PDYS-26) along with other assessments to evaluate dyskinesia severity and clinical applicability.
2 visits (Day 1 and Day 8, in-person)
Trial Site Locations
Total: 2 locations
1
Bakirçay University Çiğli Regional Education Hospital
Izmir, İ̇zmi̇r, Turkey (Türkiye), 35000
Actively Recruiting
2
Izmir Bakırçay Univercity
Izmir, Turkey (Türkiye), 35000
Actively Recruiting
Loading map...
Research Team
I
Irem Tepe Bark, PT
G
Gulbin Ergin, PT, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here